Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
Select SFBs and MFI players positioned for earnings upside: Rajiv Mehta
Non-banking financial companies are demonstrating early resilience, with collections holding firm across key segments like vehicle finance and microfinance. Despite lingering macroeconomic uncertainties and inflation,
May 21, 2026